We evaluated medications approved by the US Food and Drug Administration (FDA) for weight loss, including recently approved single agents liraglutide (Saxenda, Novo Nordisk) and semaglutide (Wegovy, Novo Nordisk), as well as the combination drugs phentermine/topiramate (Qysmia, Vivus) and bupropion/naltrexone (Contrave, Currax Pharmaceuticals) (Table 1). Semaglutide and liraglutide are glucagon-like peptide-1 (GLP-1) receptor agonists that are also approved for diabetes mellitus and given by subcutaneous injection, whereas phentermine/topiramate and bupropion/naltrexone are combination oral agents that work via other mechanisms. Other promising therapies (eg, tirzepatide) are still under investigation and were therefore not included in the scope of this review.